OncoLink at ASTRO 2000: Monday, October 23

A Phase II Randomized Trial of Synchronous Radiotherapy With Temozolomide in Brain Metastases Health Policy Expert Marc Roberts, PhD, Urges Physicians to Be on the Front Lines of Change in the Health Care System Impact of a boost dose of 16 Gy on the local control and cosmesis in patients with early breast cancer: The EORTC boost versus no boost trial Intergroup 0116 (SWOG 9008)- phase III trial of postoperative adjuvant radiochemotherapy for high risk gastric and gastroesophageal junction adenocarcinoma: Evaluation of efficacy and radiotherapy treatment planning Neuropsychological effects of fractionated, stereotactic radiation therapy (FSRT) in patients with meningiomas Panel Presentation Examines the Use of Unconventional Medical Therapies by Cancer Patients Preliminary Report of RTOG 9508: A Phase III Trial Comparing Whole Brain Irradiation Alone Versus Whole Brain Irradiation Plus Stereotactic Radiosurgery for Patients with Two or Three Unresected Brain Metastases Randomized Treatment of Brain Metastasis with Gamma Knife Radiosurgery, Whole Brain Radiotherapy or Both Randomized treatment of brain metastasis with gamma knife radiosurgery, whole brain radiotherapy or both RTOG Protocol 92-02: A phase II trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate Sequential Vs. Concurrent Chemotherapy and Radiation Therapy for Inoperable Non-Small Cell Lung Cancer (NSCLC) Analysis of Failures in a Phase III Study (RTOG 9410) Very accelerated versus conventional radiotherapy in HNSCC: Results of the GORTEC 94-02 randomized trial


7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015

Related News

Smoking Causes Over 440,000 US Deaths Each Year

Nov 30, 2015

Over 5 million years of potential life lost annually in the United States

Surgery for Spinal Metastasis Up From 2000 to 2009 in U.S.

Sep 2, 2014

In-hospital mortality rates, length of stay steady, but complications, costs up

Death Rate for All Cancers Down in U.S. From 2000 to 2009

Jan 8, 2013

Incidence of cancers down for men, stabilized in women; incidence of some cancers increasing